Global Recombinant Albumin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Albumin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Recombinant albumin is genetically engineered and derived from a rice-based expression system. It is a highly purified and completely animal-, virus-, and bacteria-free product that was developed as an alternative to plasma-derived HSA, to which it is structurally equivalent.
Recombinant Albumin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Albumin market is projected to reach US$ 121.4 million in 2029, increasing from US$ 75 million in 2022, with the CAGR of 7.2% during the period of 2024 to 2029. Demand from Cell Culture Media and Medical Supplements are the major drivers for the industry.
The Recombinant Albumin market is primarily driven by the increasing demand for high-quality and safe albumin products in various medical and research applications. Recombinant albumin, produced using biotechnology methods, offers a reliable alternative to traditional plasma-derived albumin, with reduced risk of contamination and consistent quality. The growing prevalence of chronic diseases and the need for albumin in critical care settings, drug formulation, and cell culture contribute to market growth. Moreover, the emphasis on animal-free and sustainable sourcing aligns with the adoption of recombinant albumin. However, challenges include addressing the cost-effectiveness of recombinant production methods and ensuring scalability for large-scale production. Navigating regulatory approvals and market competition, while addressing pricing pressures, are ongoing concerns. The market's success relies on continuous innovation in recombinant protein technology, collaborations between biotechnology companies and pharmaceutical manufacturers, and comprehensive research to demonstrate the safety, efficacy, and cost benefits of recombinant albumin while addressing the evolving challenges associated with protein production, quality assurance, and market acceptance.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Albumin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Albumedix
Merck
Ventria (InVitria)
NCPC
Oryzogen
HiMedia
Segment by Type
OsrHSA
ScrHSA
Cell Culture Media
Medical Supplements
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Albumin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Albumin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Albumin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Albumin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Albumin introduction, etc. Recombinant Albumin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Albumin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Recombinant Albumin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Albumin market is projected to reach US$ 121.4 million in 2029, increasing from US$ 75 million in 2022, with the CAGR of 7.2% during the period of 2024 to 2029. Demand from Cell Culture Media and Medical Supplements are the major drivers for the industry.
The Recombinant Albumin market is primarily driven by the increasing demand for high-quality and safe albumin products in various medical and research applications. Recombinant albumin, produced using biotechnology methods, offers a reliable alternative to traditional plasma-derived albumin, with reduced risk of contamination and consistent quality. The growing prevalence of chronic diseases and the need for albumin in critical care settings, drug formulation, and cell culture contribute to market growth. Moreover, the emphasis on animal-free and sustainable sourcing aligns with the adoption of recombinant albumin. However, challenges include addressing the cost-effectiveness of recombinant production methods and ensuring scalability for large-scale production. Navigating regulatory approvals and market competition, while addressing pricing pressures, are ongoing concerns. The market's success relies on continuous innovation in recombinant protein technology, collaborations between biotechnology companies and pharmaceutical manufacturers, and comprehensive research to demonstrate the safety, efficacy, and cost benefits of recombinant albumin while addressing the evolving challenges associated with protein production, quality assurance, and market acceptance.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Albumin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Albumedix
Merck
Ventria (InVitria)
NCPC
Oryzogen
HiMedia
Segment by Type
OsrHSA
ScrHSA
Segment by Application
Cell Culture Media
Medical Supplements
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Albumin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Albumin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Albumin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Albumin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Albumin introduction, etc. Recombinant Albumin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Albumin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices